Krenosin (Adenosine)

Adenosine activates A1 receptors in the heart, causing potassium efflux and hyperpolarization of AV nodal cells. This creates a short, reversible block of AV conduction, which stops re‑entrant tachyarrhythmias and provides a transient stimulus for stress testing.

The dose of Krenosin is determined by the prescribing clinician based on the patient’s condition, weight, and response. It is administered intravenously as a rapid bolus under continuous cardiac monitoring.

Adenosine is classified as Pregnancy Category B, indicating that animal studies have not shown risk but there are no well‑controlled human studies. It should be used only if the potential benefit justifies the potential risk to the fetus. Breastfeeding mothers should consult a healthcare professional.

To order Krenosin, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Unlike class I or III antiarrhythmics, adenosine works almost instantly and has a very short half‑life, making it ideal for rapid conversion of PSVT and for controlled AV block during stress testing. Its effect wears off within seconds, reducing the need for prolonged monitoring compared with longer‑acting agents.

Krenosin should be stored at 2‑8 °C (refrigerated). Keep the vial in its original packaging, protect it from light, and do not freeze or shake the solution to maintain stability.

Krenosin is given as an intravenous bolus injection, typically through a peripheral vein. Administration should be performed by trained healthcare personnel with continuous ECG monitoring to observe the rapid onset and termination of the AV block.

The most serious risks include prolonged AV block, severe bradycardia, asystole, and rare allergic reactions such as bronchospasm. Immediate medical intervention, including atropine or transcutaneous pacing, may be required if these events occur.

Krenosin is contraindicated in patients with second‑ or third‑degree AV block, sick sinus syndrome, or severe coronary artery disease without appropriate monitoring. It should also be avoided in individuals with known hypersensitivity to adenosine or any of its excipients.